Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Company Overview

Tarsus Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders. The company leverages a multidisciplinary pipeline strategy, combining small‐molecule drug discovery with novel delivery approaches to optimize tissue penetration and minimize systemic exposure. Tarsus collaborates with clinical research sites across North America and Europe to execute its global development plans and intends to explore strategic partnerships for later‐stage commercialization and distribution.

Founded in 2018 and headquartered in Westlake Village, California, Tarsus Pharmaceuticals was established by a team of industry veterans with deep experience in ophthalmology, neurology and pharmaceutical development. The company’s leadership team includes seasoned executives with track records in launching ophthalmic products and navigating regulatory pathways. Tarsus maintains corporate offices in the United States and engages with regulatory authorities to advance its portfolio toward potential approval and market launch.

Key Stats

• Today's Range: $64.56 to $66.02
• 50-Day Range: $60.67 to $77.43
• 52-Week Range: $38.51 to $85.25
• Volume: 91,879 shs
• Average Volume: 559,092 shs
• Market Capitalization: $2.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.67
• Consensus Rating: Moderate Buy

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

Tarsus Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 139th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 2 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Tarsus Pharmaceuticals has a consensus price target of $90.67, representing about 39.9% upside from its current price of $64.81.

Amount of Analyst Coverage

Tarsus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($0.74) to $2.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tarsus Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tarsus Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tarsus Pharmaceuticals has a P/B Ratio of 8.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TARS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tarsus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tarsus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.63

News Sentiment

Tarsus Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,432,035.00 in company stock.

Percentage Held by Insiders

8.97% of the stock of Tarsus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TARS Stock Analysis - Frequently Asked Questions

How have TARS shares performed this year?

Tarsus Pharmaceuticals' stock was trading at $81.88 at the beginning of 2026. Since then, TARS shares have decreased by 20.8% and is now trading at $64.81.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings data on Monday, February, 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The business earned $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative trailing twelve-month return on equity of 19.63%.
Read the conference call transcript.

When did Tarsus Pharmaceuticals IPO?

Tarsus Pharmaceuticals (TARS) raised $88 million in an IPO on Friday, October 16th 2020. The company issued 5,500,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (3.01%), Allspring Global Investments Holdings LLC (0.31%), Bank of New York Mellon Corp (0.25%) and Calamos Advisors LLC (0.10%). Insiders that own company stock include William J Phd Link, Seshadri Neervannan, Bryan Wahl, Aziz Mottiwala, Jeffrey S Farrow, Dianne C Whitfield, Bobak R Azamian, Elizabeth Yeu Lin, Andrew D Goldberg and Jose M Trevejo.
View institutional ownership trends.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tarsus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/23/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TARS
• CIK: 1819790
• Web: www.tarsusrx.com
• Phone: 949-409-9820
• Fax: N/A
• Employees: 50
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Tarsus Pharmaceuticals: $90.67
• High Price Target: $100.00
• Low Price Target: $68.00
• Potential Upside/Downside: +39.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.42 million
• Net Margins: -14.72%
• Pretax Margin: -14.26%
• Return on Equity: -19.63%
• Return on Assets: -12.70%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 3.85
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $451.36 million
• Price / Sales: 6.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.09 per share
• Price / Book: 8.01

Miscellaneous

• Outstanding Shares: 43,020,000
• Free Float: 39,165,000
• Market Cap: $2.79 billion
• Optionable: Optionable
• Beta: 0.52